Taking some chips off the table (Vopak)

Last August, there was a lot of pessimism around Vopak in the markets. Since then, the company has performed very well and the share price increased from €22.23 to around €34.12, while collecting a dividend of €1.30 in between.

This leaves a performance in Euro of almost 60% incl. dividend and might be a good time to take some chips off the table. Congratulations if you have been holding Vopak in the last year!

Comments

Post a Comment

Popular posts from this blog

Domino's Pizza Group plc (LSE:DOM)

Intro Domino's Pizza Group is the exclusive master franchise holder for Domino's Pizza in the United Kingdom and Ireland. The company doesn't own the Domino's brand itself – it licenses it from the US-based Domino's Pizza Inc – but it does control the entire UK and Irish operation: the supply chain, the digital platform, and the franchise relationships with the local operators who run about 1,400 stores. The UK franchise dates back to 1985, when the first store opened in Luton. The master franchise was acquired in 1993. For a while, management tried to replicate the model abroad – Norway, Sweden, Iceland, Switzerland – but those ventures proved costly and distracting. Between 2019 and 2021, the company exited all its directly operated international markets and refocused entirely on the UK and Ireland. It was the right call. 2025 brought more disruption at the top. CEO Andrew Rennie departed by mutual agreement in November after just two years in the role, repo...
Read more

Tecan Group AG (SWX:TECN)

Intro Tecan Group is a Swiss laboratory automation specialist founded in 1980 by four engineers working out of a home office in Switzerland. Over the past four decades, the company has grown into a global leader in liquid handling, robotic workstations and detection instruments – the kind of equipment that pharma companies, diagnostic labs and university research departments rely on to process samples at scale. If you've had a blood test or a COVID PCR swab, there's a decent chance a Tecan-built machine was involved somewhere along the chain. The company operates in two segments. Life Sciences Business sells instruments and consumables directly to end users. Partnering Business develops and manufactures OEM instruments and components that are then sold by diagnostic and medtech partners under their own brands. The stock has dropped roughly 80% from its September 2021 peak of CHF 602, hammered by a post-pandemic destocking cycle, reduced pharma and biotech R&D spending...
Read more

Rotation Time

Some of the companies discussed on this blog over the years have reached – or come close to – their estimated intrinsic value. With the current market offering a number of compelling new opportunities (more on that soon), it makes sense to rotate out of the winners and redeploy the capital. Two positions to write about: Basler Kantonalbank was first discussed in April 2021. The participation certificates have performed very well since then, reaching the price target. Excluding dividends, the capital gain amounts to roughly 67%. Including the steady dividend payments over the holding period, the total return is even higher. A nice outcome for a quiet, under-the-radar Swiss cantonal bank.   Fresenius SE was highlighted in October 2020 at €34.06. The new management's strategic overhaul – simplifying the group structure, sharpening the focus on Kabi and Helios, and restoring margin discipline – has started to bear fruit, and the market has taken notice. The stock has gained more th...
Read more